Sirtris Pharmaceuticals to Webcast Conference Call for Second Quarter 2007 Financial Results
07 August 2007 - 10:00PM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging, announced today announced that it will
report financial results for the second quarter of 2007 on Monday,
August 13, 2007, after the U.S. financial markets close. Management
will provide an update on the Company and discuss second quarter
results via conference call on Monday, August 13, 2007, at 4:30
p.m. EDT. To access the call, please dial 800-289-0572 (domestic)
or 913-981-5543 (international) five minutes prior to the start
time and provide the passcode 2478956. A replay of the call will be
available from 6:00 p.m. EDT on August 13, 2007 until August 24,
2007. To access the replay, please dial 888-203-1112 (domestic) or
719-457-0820 (international), and provide the passcode 2478956. A
live audio webcast of the call also will be available on the
"Investors" section of the Company's website,
www.sirtrispharma.com. An archived webcast will be available on the
Sirtris website approximately one hour after the call and will be
archived for 14 days. About Sirtris Pharmaceuticals Sirtris
Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes that control the aging process. The company's
headquarters are in Cambridge, Massachusetts. This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 concerning Sirtris
Pharmaceuticals. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results, the Company's potential inability to
initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the�Company to gain market acceptance of the Company's
product candidates, and those other risks factors�that can be found
in the�Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles